Cost-utility of angiotensin-converting enzyme inhibitor compared to thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as comorbidity
MetadataShow full item record
OBJECTIVE: To examine the cost-effectiveness of angiotensin-converting enzyme inhibitor-based (ACEI) treatment compared to thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as an outcome along with cardiovascular outcomes from the Australian government perspective. DESIGN AND METHOD: We used a cost-utility analysis to estimate the incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) gained. Data on cardiovascular events and new-onset of diabetes were used from the Second Australian National Blood Pressure Study, a randomized clinical trial comparing diuretic-based (hydrochlorothiazide) versus ACEI-based (enalapril) treatment in 6083 elderly (age 65yrs or more) hypertensive patients over a median 4.1-year period. For this economic analysis, the total study population was stratified into two groups. Group A was restricted to participants diabetes-free at baseline (n?=?5,642); and Group B was restricted to participants with pre-existing diabetes mellitus (Type I or Type II) at baseline (n?=?441). Data on utility scores for different events were used from available published literatures; whereas, treatment and adverse event management cost were calculated from direct health care costs available from Australian Government reimbursement data. Quality of life and costs were discounted at 5% per annum. One-way and probabilistic sensitivity analyses were performed to assess the uncertainty around utilities and cost data. RESULTS: After a treatment period of five years, for Group A the ICER was AUD 27,698 (Euro 18,004; AUD 1~ &OV0556; 0.65) per QALY gained comparing ACEI-based with diuretic-based treatment (sensitive to the utility value for new-onset diabetes). In Group B, ACEI-based treatment was a dominant strategy (both more effective and cost-saving). On probabilistic sensitivity analysis, the ICERs per QALY gained were always below AUD 50,000 for Group B; whereas for Group A the probability of being below AUD 50,000 was 85%. CONCLUSIONS: Although the dispensed price of diuretic-based treatment of hypertension in the elderly is lower, upon considering the potential enhanced likelihood of the development of diabetes in addition to the costs of treating cardiovascular disease, ACEI-based treatment may be a more cost-effective strategy in this population.
Showing items related by title, author, creator and subject.
Cost–Utility of Angiotensin-Converting Enzyme Inhibitor-Based Treatment Compared With Thiazide Diuretic-Based Treatment for Hypertension in Elderly Australians Considering Diabetes as ComorbidityChowdhury, E.; Ademi, Z.; Moss, J.; Wing, L.; Reid, Christopher (2015)Abstract: The objective of this study was to examine the cost-effectiveness of angiotensin-converting enzyme inhibitor (ACEI)-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly ...
Short-and long-term survival in treated elderly hypertensive patients with or without diabetes: Findings from the second Australian national blood pressure studyChowdhury, E.; Owen, A.; Ademi, Z.; Krum, H.; Johnston, C.; Wing, L.; Nelson, M.; Reid, Christopher (2014)Background: We sought to determine the incidence of newly diagnosed diabetes in treated elderly hypertensive patients and the prognostic impact of diabetes on long-term survival. Methods: The Second Australian National ...
Chowdhury, E.; Langham, R.; Ademi, Z.; Owen, A.; Krum, H.; Wing, L.; Nelson, M.; Reid, Christopher (2015)Background and objectives Evidence relating the rate of change in renal function, measured as eGFR, after antihypertensive treatment in elderly patients to clinical outcome is sparse. This study characterized the rate of ...